Table 3.

Plasma and lung concentrations of favipiravir after administration of a single dose or multiple dose of favipiravir.

Time post-treatment	Single dose				Multiple dosea (Day 3)
	Dose	Plasma (µg/mL)	Lung (µg/g)	L/p ratio	Dose	Plasma (µg/mL)	Lung (µg/g)	L/p ratio
0.5 h	25 mg	372 ± 47.5	216 ± 39	0.58 ± 0,04	75 mg/day TID
1 h		279 ± 49.9
5 h		135 ± 49.0	81.3 ± 24	0.62 ± 0.10
8 h		5.77 ± 1.34
12 h		1.43b				29.9 ± 9.83	16.0 ± 4.87	0.44 ± 0,07
0.5 h	12.5 mg	166 ± 52.0	90.7 ± 12.7	0.58 ± 0.14	37.5 mg/day TID
1 h		155 ± 20.6
5 h		10.7 ± 5.16	3.84 ± 1.49	0.37 ± 0.052
8 h		1.94 ± 0.06
12 h		0.16b				2.57 ± 1.22	1.36 ± 0.14	0.35 ± 0,03
0.5 h	6.25 mg	86.3 ± 4.11	50.2 ± 16.4	0.58 ± 0.17	18.75 mg/day TID
1 h		35.2 ± 27.8
5 h		2.90 ± 0.25	1.09 ± 0.05	0.38 ± 0.05
8 h		0.56 ± 0.16
12 h		0.05b				0.31 ± 0.14	Not detected	NA

NA not applicable.

Data represent mean ± SD; three animals for each condition except at multiple dose (n = 9 for plasma; n = 3 for lung); details in Supplementary Data 9.

^aPK realized after 3 days of favipiravir administered three times a day, at the end of the dosing interval (trough concentrations).

^bExtrapolated C_12h.